EGFR and non-small cell lung carcinoma: The gefitinib, which is a specific inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has been shown to suppress the activation of EGFR signaling essential for survival in non-small cell lung cancer (NSCLC) cell lines.